Исследование полиморфизма генов ариламин N-ацетилтрансфераз и ассоциации полиморфных вариантов с раком легкого у европеоидов г. Новосибирска
Диссертация
Для выявления подобных ассоциаций используют методы аналитической эпидемиологии, наиболее распространенными из которых являются когортные исследования и менее трудоемкие, но достаточно надежные исследования «случай-контроль». В настоящей работе было проведено исследование, построенное по типу «случай-контроль», направленное на поиск возможных ассоциаций распространенных полиморфных вариантов… Читать ещё >
Список литературы
- Викторова Т. В, Корытина Г. Ф, Макарова О. В. и др. Полиморфизм гена ариламин-К-ацетилтрансферазы 2 у народов Волго-Уральского региона // Мол. Биология. 2003. — Т. 37. — С. 971−974.
- Глотов С, Наседкина Т. В, Иващенко Т. Е. и др. Разработка биочипа для анализа полиморфизма генов системы биотрансформации // Мол. Биология. 2005. -Т. 36.-№ 4.-С. 563−584.
- Гуляева Л. Ф, Вавилин В. А, Ляхович В. В. Ферменты биотрансформации ксенобиотиков в химическом канцерогенезе. Аналит. обзор. Новосибирск, 2000. -85 с.
- Канцерогенез / Под ред. Д. Г. Заридзе. М.: Медицина, 2004. — 576 с.
- Ляхович В. В, Вавилин В. А, Гуткина Н. И. и др. Гены и ферменты системы метаболизма ксенобиотиков в онкопатологии // Вопр. мед. хим. 1997. — Т. 43. — № 5.-С. 330−338.
- Макарова С. И, Додунова Е. М, Иванова Г. Г. и др. Полиморфизм гена ариламин Ы-ацетилтрансферазы 2 ассоциирован с риском развития атопического дерматита // Бюлл. Эксп. Биол. Мед. 2005. — Т. 139. — № 5. — С. 628−631.
- Макарова С. И, Вавилин В. А, Ляхович В. В, Гавалов С. М. Аллель ИАТ2*5 -фактор устойчивости к заболеванию бронхиальной астмой у детей // Бюлл. Эксп. Биол. Мед. 2000. — № 6. — С. 677−679.
- Маниатис Т, Фрич Э, Сэмбрук Дж. Методы генетической инженерии. Молекулярное клонирование. М.: Мир, 1984.-480 с.
- Мерабишвили В. М, Дятченко О. Т. Статистика рака легкого (заболеваемость, смертность, выживаемость) // Практическая онкология. 2000. -№ 3.- С. 3−7.
- Пузырев В. П, Степанов В. А. Патологическая анатомия генома человека. -Новосибирск: Наука, 1997. 224 с.
- Трахтенберг А.Х., Чиссов В. И. Клиническая онкопульмонология. М.: ГЕОТАР Медицина, 2000. — 600 с.
- Флетчер Р., Флетчер С, Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины. М.: Медиа Сфера, 1998. — 352 с.
- Adedoyin A., Stiff D.D., Smith D.C. et al. All-irans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes // Cancer Chemother. Pharmacol. 1998. — V. 41. — P. 133−139.
- Agundez J.A., Jimenez-Jimenez F.J., Luengo A. et al. Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson’s disease // Neurology. -1998.-V. 51.-P. 1587−1592.
- Agundez J.A., Martinez C., Olivera M. et al. Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk // Br. J. Cancer. 1998. — V. 78. — P. 1361−1367.
- Andres H.H., Klem A.J., Schopter L.M. et al. On the active site of liver acetyl-CoA arylamine N-acetyltransferase from rapid acetylator rabbits (III/J) // J. Biol. Chem. -1988.-V. 263.-P. 7521−7527.
- Anitha A., Banerjee M. Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India // Int. J. Mol. Med. 2003. — V. 11. — P. 125−131.
- Arias T.D., Jorge L.F., Griese E.U. et al. Polymorphic N-acetyltransferase (NAT2) in Amerindian populations of Panama and Columbia: High frequencies of point mutation 857A, as found in allele S3/M3 // Pharmacogenetics. 1993. — V. 3. — P. 328−331.
- Bandmann O., Vaughan J.R., Holmans P. Detailed genotyping demonstrates association between the slow acetylator genotype for N-acetyltransferase 2 (NAT2) and familial Parkinson’s disease // Mov. Disord. 2000. — V. 15. — P. 30−35.
- Badawi A.F., Hirvonen A., Bell D.A. et al. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder // Cancer Res. 1995. — V. 55. — P. 5230−5237.
- Barrett J.H., Smith G., Waxman R. et al. Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer // Carcinogenesis. 2003. — V. 24. — P. 275−282.
- Bell D.A., Badawi A.F., Lang N.P. et al. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher Nacetylation activity in bladder and colon tissue // Cancer Res. 1995. — V. 55. — P. 52 265 229.
- Bell D.A., Stephens E.A., Castranio T. et al. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer // Cancer Res. -1995.-V. 55.-P. 3537−3542.
- Bell D.A., Taylor J.A., Butler M.A. et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans // Carcinogenesis. 1993. — V. 13. — P. 1689−1692.
- Belogubova E.V., Kuligina E.S., Togo A.V. et al. 'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility // Cancer Lett. 2005. — V. 221. — P. 177−183.
- Blum M., Demierre A., Grant D.M. et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans // Proc. Natl. Acad. Sci. USA. — 1991. — V. 88.-P. 5237−5241.
- Blum M., Grant D.M., Demierre A., Meyer U.A. Nucleotide sequence of a full-length cDNA for arylamine N-acetyltransferase from rabbit liver // Nucleic Acids Res.1989.-V. 17. P. 3589.
- Blum M., Grant D.M., McBride W. et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression // DNA Cell Biol.1990.-V. 9.-P. 192−203.
- Borlak J., Reamon-Buettner S.M. N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients // BMC Med. Genet. 2006. — V. 7. -P. 58.
- Bouchardy C., Mitrunen K., Wikman H. et al. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk // Pharmacogenetics. 1998. — V. 8. — P. 291−298.
- Boukouvala S., Price N., Plant K.E., Sim E. Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice // Biochem J. 2003. — V. 375. — P. 593−602.
- Boukouvala S., Sim E. Structural analysis of the genes for human arylamine N-acetyltransferases and characterization of alternative transcripts // Basic Clin. Pharmacol. Toxicol. 2005. — V. 96. — P. 343−351.
- Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? // Carcinogenesis. 2002. — V. 23. — P. 381−387.
- Brockton N., Little J., Sharp L., Cotton S.C. N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review // Am. J. Epidemiol. 2000. — V. 151. — P. 846 861.
- Bruhn C., Brockmoller J., Cascorbi I. et al. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1) // Biochem. Pharmacol. 1999. — V. 58. — P. 1759−1764.
- Butcher N.J., Arulpragasam A., Pope C., Minchin R.F. Identification of a minimal promoter sequence for the human N-acetyltransferase Type I gene that binds AP-1 (activator protein 1) and YY-1 (Yin and Yang 1) // Biochem J. 2003. — V. 376. — P. 441 448.
- Butcer N.J., Boukouvala S., Sim E., Minchin R.F. Pharmacogenetics of the arylamine N-acetyltransferases // Pharmacogenomics J. 2002. — V. 2. — P. 30−42.
- Butcher N.J., Ilett K.F., Minchin R.F. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations // Pharmacogenetics. 1998. — V. 8. — P. 67−72.
- Butcher N.J., Ilett K.F., Minchin R.F. Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells // Mol. Pharmacol. 2000. — V. 57. — P 468−473.
- Cascorbi I., Brockmoller J., Bauer S. et al. NAT2* 12A (803A>G) codes for rapid arylamine N-acetylation in humans // Pharmacogenetics. 1996. — V. 6. — P. 257−259.
- Cascorbi I., Brockmoller J., Mrozikiewicz P.M. et al. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer // Cancer Res. 1996. — V. 56. — P. 3961−3966.
- Cascorbi I., Brockmoller J., Roots I. Molecular-epidemiological aspects of carcinogenesis: the role of xenobiotic metabolizing enzymes // Int. J. Clin. Pharmacol. Ther. 2002. — V. 40. — P. 562−563.
- Cascorbi I., Drakoulis N., Brockmoller J. et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity // Am. J. Hum. Genet. 1995. — V. 57. — P. 581−592.
- Cascorbi I., Roots I., Brockmoller J. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT 1*101 I Cancer Res. 2001. — V. 61. — P. 5051−5056.
- Chang H.L., Hung C.F., Yeh C.C. Paeonol promoted 2-aminofluorene and p-aminobenzoic acid acetylation by mononuclear leucocytes from Sprague-Dawley rats // Cytobios. 2000. — V. 103.-P. 149−258.
- Chen J., Stampfer M.J., Hough H.L. et al. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer // Cancer Res. -1998.-V. 58.-P. 3307−3311.
- Chiou H.L., Wu M.F., Chien W.P. et al. NAT2 fast acetylator genotype if associated with an increased risk of lung canser among never-smoking women in Taiwan // Cancer Lett. 2005. — V. 223. — P. 93−101.
- Chung J.G., Chang H.L., Lin W.C. et al. Effects of ibuprofen on arylamine N-acetyltransferase activity in human colon tumour cells // J. Appl. Toxicol. 1999. — V. 19.-P. 1−6.
- Chung J.G., Chang H.L., Lin W.C. et al. Inhibition of N-acetyltransferase activity and DNA-2-aminofluorene adducts by glycyrrhizic acid in human colon tumour cells // Food Chem. Toxicol. 2000. — V. 38. — P. 163−172.
- Chung J.G., Chang H.L., Yeh C.C. et al. Effects of immunomodulator tilorone on the acetylation of 2-aminofluorene and DNA-2-aminofluorene in rats // Anticancer Res. -2000.-V. 20.-P. 467−473.
- Cribb A.E., Grant D.M., Miller M.A., Spielberg S.P. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes // J. Pharmacol. Exp. Ther. -1991.-V. 259.-P. 1241−1246.
- Dandara C., Masimirembwa C.M., Magimba A. et al. Arylamine N-acetyltransferase (NAT2) genotypes in Africans: the identification of a new allele with nucleotide changes 481C>T and 590G>A // Pharmacogenetics. 2003. — V. 13. — P. 5558.
- Debiec-Rychter M, Land S.J., King C.M. Histological localization of acetyltransferases in human tissue // Cancer Lett. 1999. — V. 143. — P. 99−102.
- Deguchi T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase ofhuman liver//J. Biol. Chem. 1992. -V. 267. -P. 18 140−18 147.
- Deitz A.C., Doll M.A., Hein D.W. A restriction fragment length polymorphism assay that differentiates human N-acetyltransferase-1 (NATI) alleles // Anal. Biochem. -1997.-V. 253.-P. 219−224.
- Deitz A.C., Zheng W., Leff M.A. et al. N-acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women // Cancer Epidemiol. Biomarkers Prev. 2000. — V. 9. — P. 905−910.
- Dhaini H.R., Levy G.N. Arylamine N-acetyltransferase 1 (NAT1) genotypes in a Lebanese population // Pharmacogenetics. 2000. — V. 10. — P. 79−83.
- Dupret J-M, Rodrigues-Lima F. Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases // Curr. Med. Chem. 2005. — V. 12. — P. 763-r 771.
- Ebisawa T., Sasaki Y., Deguchi T. Complementary DNAs for two arylamine N-acetyltransferases with identical 5' non-coding regions from rat pineal gland // Eur. J. Biochem. 1995. — V. 228. — P. 129−137.
- Estrada-Rodgers L., Levy G.N., Weber W.W. Characterization of a hormone response element in the mouse N-acetyltransferase 2 (Natl*) promoter // Gene Expression. 1998. — V. 7. — P. 13−24.
- Evans D.A. N-acetyltransferase // Pharmacol. Therapeut. 1989. — V. 42. — P. 157−234.
- Evans T.L. Highlights from the tenth world conference on lung cancer // Oncologist. 2004. — V. 9. — P. 232−238.
- Farker K., Schotte U., Scheele J., Hoffmann A. Impact of N-acetyltransferase polymorphism (NAT2) in hepatocellular carcinoma (HCC) an investigation in a department of surgical medicine // Exp. Toxicol. Pathol. — 2003. — V. 54. — P. 387−391.
- Fretland A.J., Doll M.A., Leff M.A., Hein D.W. Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1 // Pharmacogenetics. 2001. V. 11. — P. 511−520.
- Fretland A.J., Leff M.A., Doll M.A., Hein D.W. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms // Pharmacogenetics. 2001. — V. 11. — P. 207−215.
- Fronhoffs S., Bruning T., Ortiz-Pallardo E. et al. Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, * 10, * 11, *14 and *17 polymorphism in squamous cell cancer of head and neck // Carcinogenesis. 2001. — V. 22. — P. 1405−1412.
- Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M. et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and P, glycoprotein in a Russian population // Eur. J. Clin. Pharmacol. 2003. — V.59. — P. 303 312.
- Galton D.J., Ferns G.A. Genetic markers to predict polygenic disease: a new problem for social genetics // QJM. 1999. — V. 92. — P. 223−232.
- Garte S. Metabolic susceptibility genes as cancer risk factors: time for a reassessment? // Cancer Epidemiol. Biomarkers Prev. 2001. — V. 10. — P. 1233−1237.
- Goodfellow G.H., Dupret J-M., Grant D.M. Identification of amino acids impairing acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2 //Biochem. J. 2000. — V. 348. — P. 159−166.
- Grant D.M., Blum M., Beer M., Meyer U.A. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes // Mol. Pharmacol. 1991. — V. 39. — P. 184−191.
- Grant D.M., Blum M., Demierre A., Meyer U.A. Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation // Nucl. Acids Res. 1989. — V. 17. — P. 3978.
- Grant D.M., Hughes N.C., Janezic S.A. et al. Human acetyltransferase polymorphisms // Mutat. Res. 1997. — V. 376. — P. 61−70.
- Grant D.M., Morike K., Eichelbaum M., Meyer U.A. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by descreased or absent arylamine N-acetyltransferase in human liver // J. Clin. Invest. 1990. — V. 85. — P. 968 972.
- Gross M., Kruisselbrink T., Anderson K. et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population // Cancer Epidemiol. Biomarkers Prev. 1999. — V. 8. — P. 683−692.
- Habalova V., Salagovic J., Kalina I., Stubna J. A pilot study testing the genetic polymorphism of N-acetyltransferase 2 as a risk factor in lung cancer // Neoplasma. -2005.-V. 52.-P. 364−368.
- Hadasova E., Siegmund W., Franke G. et al. // Drug oxidation and N-acetylation in rats pretreated with subtoxic doses of streptolysin 0 // Biochem. Pharmacol. 1991. -V. 42.-P. 702−704.
- Hall P.M., Stupans I., Burgess W. et al. Immunohistochemical localization of NADPH-cytochrome P450 reductase in human tissues // Carcinogenesis. 1989. — V. 10. -P. 521−530.
- Hamasaki T., Inatomi H., Katoh T. et al. N-acetylteansferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men // Int. J. Urol. -2003.-V. 10.-P. 167−173.
- Haugen A., Ryberg D., Mollerup S. et al. Gene-environment interactions in human lung cancer // Toxicol. Lett. 2000. — V. 112. — P. 233−237.
- Hein D.W. N-acetyltransferase 2 gene genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk // Oncogene. 2006. — V. 25. -P. 1649−1658.
- Hein D.W., Doll M.A., Fretland A.J. et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms // Cancer Epidemiol. Biomark. Prev. -2000. V. 9. — P. 29−42.
- Hein D.W., Doll M.A., Rustan T.D. et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases // Carcinogenesis. 1993. — V. 14. — P. 1633−1638.
- Hein D.W., Ferguson R.J., Doll M.A. et al. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes // Hum. Mol. Genet. 1994. — V. 3. — P. 729−734.
- Hein D.W., Grant D.M., Sim E. Update on consensus arylamine N-acetyltransferases nomenclature // Pharmacogenetics. 2000. — V. 10. — P. 291−292.
- Hein D.W., Rustan T.D., Ferguson R.J. et al. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases // Arch. Toxicol. 1994. — V. 68. — P. 129−133.
- Henning S., Cascorbi I., Munchow B. et al. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk // Pharmacogenetics. 1999. — V. 9. — P. 103−111.
- Hickman D., Palamanda J.R., Unadkat J.D., Sim E. Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli 1/ Biochem. Pharmacol. 1995. — V. 5. — P. 697−703.
- Hickman D., Pope J., Patil S.D. et al. Expression of arylamine N-acetyltransferase in human intestine // Gut. 1998. — V. 42. — P. 402−409.
- Hickman D., Risch A., Buckle V. et al. Chromosomal localization of human genes for arylamine N-acetyltransferase // Biochem. J. 1994. — V. 297. — P. 441−445.
- Hickman D., Risch A., Camilleri J.P., Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants // Pharmacogenetics. 1992. — V. 2. — P. 217−226.
- Hickman D., Sim E. N-acetyltransferase polymorphism: comparison of phenotype and genotype in humans //Biochem. Pharmacol. -1991. V. 42. — P. 1007−1014.
- Holton S.J., Dairou J., Sandy J. et al. Structure of Mesorhizobium loti arylamine N-acetyltransferase 1 // Acta Crystallograph. 2005. — V. 61. — P. 14−16.
- Hou S-M., Ryberg D., Fait S. et al. GSTM1 and NAT2 polymorphisms in operable and non-operable lung cancer patients // Carcinogenesis. 2000. — V. 21. — P. 49−54.
- Hubbard A., Moyes C., Wyllie A.H. et al. N-acetyltransferase 1: two polymorphisms in coding sequence identified in colorectal cancer patients // Br. J. Cancer. 1998. — V. 77. — P. 913−916.
- Hung R.J., Boffetta P., Brockmoller J. et al. CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis // Carcinogenesis. 2003. — V. 24. — P. 875−882.
- Husain A., Barker D.F., States J.C. et al. Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1) // Pharmacogenetics. 2004. — V. 14. — P. 397- 406.
- Ilett K.F., Chiswell G.M., Spargo R.M. et al. Acetylation phenotype and genotype in arboriginal leprosy patients from the north-west region of Western Australia // Pharmacogenetics. 1993. — V. 3. — P. 264−269.
- Ilett K.F., David B.M., Detchon P. et al. Acetylation phenotype in colorectal carcinoma // Cancer Res. 1987. — V. 47. — P. 1466−1469.
- Ilett K.F., Ingram D.M., Carpenter D.S. et al. Expression of monomorphic and polymorphic N-acetyltransferases in human colon // Biochem. Pharmacol. 1994. — V. 47.-P. 914−917.
- Inatomi H., Katoh T., Kawamoto T., Matsumoto T. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese // Int. J. Urol. 1999. -V.6.-P. 446−454.
- Kadlubar F.F., Badawi A.F. Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis // Toxicol. Lett. 1995. — V. 82−83. -P. 627−632.
- Katoh T., Kaneko S., Boissy R. et al. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people //Carcinogenesis. 1998.-V. 19.-P. 1803−1807.
- Kawamura A., Graham J., Mushtaq A. et al. Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening // Biochem. Pharmacol. 2005. — V. 69. — P. 347−359.
- Kivisto K.T., Fritz P., Linder A. et al. Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue // Histochemistry. 1995. — V. 103. — P. 25−29.
- Kristiansen E., Meyer 0., Thorup I. The ability of two cooked food mutagens to induce aberrant crypt foci in mice // Eur. J. Cancer Prev. 1997. — V. 6. — P. 53−57.
- Kukongviriapan V., Phromsopha N., Tassaneeyakul W. et al. Inhibitory effects of polyphenolic compounds of human arylamine N-acetyltransferase 1 and 2 // Xenobiotica. -2006.-V. 36.-P. 15−28.
- Land S.J., Jones R.E., King C.M. Biochemical and genetic analysis of two acetyltransferases from hamster tissues that can metabolise aromatic amine derivatives // Carcinogenesis.-1994.-V. 15.-P. 1585−1595.
- Lang N.P., Chu D.Z., Hunter C.F. et al. Role of aromatic amine acetyltransferase in human colorectal cancer // Arch. Surg. 1986. — V. 121. — P. 1259−1261.
- Lee B.L., Wong D., Benowitz N.L., Sullam P.M. Altered patterns with acquired immunodeficiency syndrome // Clin. Pharmacol. Ther. 1993. — V. 53. — P. 529−535.
- Lee S-Y., Lee K-A., Ki C-S. et al. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population // Clin. Chem. 2002. — V. 48. — P. 775 777.
- Levy M., Caraco Y., Geisslinger G. Drug acetylation in liver disease // Clin. Pharmacokinet. 1998. -V. 34. — P. 219−226.
- Li Y.C., Hung C.F., Yeh F.T. et al. Luteolin-inhibited arylamine N-acetyltransferase activity and DNA-2-aminofluorene adduct in human and mouse leukaemia cells // Food Chem. Toxicol. 2001. — V. 39. — P. 641−647.
- Lin H.J., Han C-Y., Lin B.K., Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferse (NAT2) gene // Pharmacogenetics. -1994.-V. 4.-P. 125−134.
- Lin H.J., Probst-Hensch N.M., Hughes N.C. et al. Variants of N-acetyltransferase NAT1 and case-control study of colorectal adenomas // Pharmacogenetics. 1998. — V. 8.-P. 269−281.
- Liu F., Zhang N., Hanna P.E. et al. Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation // J. Mol. Biol. 2006. — V. 361. — P. 482−492.
- Lower G.M., Nilsson T., Nelson C.E. et al. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. // Environ. Health Perspect. 1979. — V. 29. — P. 71−79.
- Mace K., Bowman E.D., Vautravers P. et al. Characterization of xenobiotic-metabolizing enzyme expression in human bronchial mucosa and peripheral lung tissues // Eur. J. Cancer. 1998. — V. 34. — P. 914−920.
- Martinez C., Agundez J.A., Olivera M. et al. Lung cancer and mutations at the polymorphic NAT2 gene locus // Pharmacogenetics. 1995. — V. 5. — P. 207−214.
- Meisel P. Arylamine N-acetyltransferases and drug response // Pharmacogenomics. 2002. — V. 3. — P. 349−366.
- Meyer U.A., Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism // Annu. Rev. Pharmacol. Toxicol. 1997. — V. 37. — P. 269−296.
- Minchin R.F. Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells // Biochem. J. 1995. -V. 307.-P. 1−3.
- Mitchell K. R, Warshawsky D. Xenobiotic inducible regions of the human arylamine N-acetyltransferase 1 and 2 genes // Toxicol. Lett. 2003. — V. 139. — P. 11−23.
- Mrozikiewicz P.M., Cascorbi I, Brockmoller J, Roots I. Determination and allelic allocation of seven nucleotde transitions within the arylamine N-acetyltransferase gene in the Polish pooulation // Clin. Pharmacol. Ther. 1996. — V. 59. — P. 376−382.
- Mushtaq A, Payton M, Sim E. The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity // J. Biol. Chem. 2002. — V. 277. — P. 12 175−12 181.
- Nagao M, Wakabayashi K, Ushijima T. et al. Human exposure to carcinogenic heterocyclic amines and their mutational fingerprints in experimental animals // Environ. Health Perspect. 1996. — V. 104. — P. 497−501.
- Nebert D.W. Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants. // Clin. Chem. Lab. Med. -2000. V. 38. — P. 857 861.
- Nebert D.W. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? // Clin. Genet. 1999. — V. 56. — P. 247−258.
- Nebert D. W, Roe A.L. Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer // Sci. Total. Environ. 2001. — V. 274. — P. 93−102.
- Nwankwo J. O, Garba M. A, Chinje C.E. et al. Possible chloroquine-induced modification of N-acetylation of isoniazid modification of N-acetylation of isoniazid and sulphadimidine in the rat // Biochem. Pharmacol. 1990. — V. 40. — P. 654−659.
- Ognjanovic S., Yamamoto J., Maskarinec G., Marchand L.L. NAT2, meat consumption and colorectal cancer incidence: an ecological study among 27 countries // Cancer Causes Control. 2006. — V. 17. — P. 1175−1182.
- Ohsako S., Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver // J. Biol. Chem. 1990. -V. 265.-P. 4630−4634.
- O’Neil W.M., Drobitch R.K., MacArthur R.D. et al. Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype // Pharmacogenetics. 2000. — V. 10. — P. 171−182.
- O’Neil W.M., Gilfix B.M., DiGirolamo A. et al. N-acetylation among HIVpositive patients and patients with AIDS: when is fast, fast and slow, slow? // Clin. Pharmacol. Ther. 1997. — V. 62. — P. 161 -271.
- Oyama T., Kawamoto T., Mizoue T. et al. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation // Anticancer Res. -1997.-V. 17.-P. 577−581.
- Pacifici G.M., Bencini C., Rane A. Acetyltransferase in humans: development and tissue distribution // Pharmacology. 1986. — V. 32. — P. 283−291.
- Payton M.A. The first 3D structure of arylamine N-acetylnransferase reveals a protease-like catalytic triad // Trends Pharmacol. Sci. 2000. — V. 21. — P. 329−330.
- Payton M.A., Sim E. Genotyping human arylamine N-acetyltransferase type 1 (NAT1) // Biochem. Pharmacol. 1998. — V. 55. — P. 361−366.
- Perera F.P. Environment and cancer: who are susceptible? // Science. 1997. — V. 287.-P. 1068−1073.
- Pink J. C, Messing E. M, Reznikoff C.A. et al. Correlation between N-acetyltransferase activities in uroepithelia and in vivo acetylator phenotype // Drug Metab. Dispos. 1992. — V. 20. — P. 559−565.
- Pompeo F, Brooke E, Kawamura A. et al. The pharmacogenetics of NAT: structural aspects // Pharmacogenomics. 2002. — V. 3. — P. 19−30.
- Probst-Hensch N. M, Bell D. A, Watson M.A. et al. N-acetyltransferase 2 phenotype but not NATI* 10 genotype affects aminobiphenil-gemoglobin adduct levels // Cancer Epidemiol. Biomarkers Prev. 2000. — V. 9. — P. 619−623.
- Reeves P. T, Minchin R. F, Ilett K.F. In vivo mechanisms for the enhanced acetylation of sulfamethazine in the rabbit after hydrocortisone treatment // J. Pharmacol. Exp. Ther. 1989. — V. 248. — P. 348−352.
- Riddle B, Jencks W.P. Acetyl-coenzyme A: arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate // J. Biol. Chem. 1971. — V. 246. — P. 3250−3258.
- Rocha L, Garcia C, de Mendonca A. et al. N-acetyltransferase (NAT2) genotype and susceptibility of sporadic Alzheimer’s disease // Pharmacogenetics. 1999. — V. 9. -P. 9−15.
- Rodrigues-Lima F, Cooper R. N, Goudeau B. et al. Skeletal muscles express the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase // J. Histochem, Cytochem. 2003. — V. 51. — P. 789−796.
- Rodrigues-Lima F, Dupret J-M. Regulation of the activity of the human drug metabolizing enzyme arylamine N-acetyltransferase 1: role of genetic and non genetic factors // Curr. Pharm. Des. 2004. — V. 10. — P. 2519−2524.
- Rodriguez JW., Kirlin W.G., Ferguson R.J. et al. Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol // Arch. Toxicol. 1993. — V. 67. — P. 445−452.
- Rothen J.P., Haefeli W.E., Meyer U.A. et al. Acetaminophen is an inhibitor of hepatic N-acetyltransferase 2 in vitro and in vivo // Pharmacogenetics. 1998. — V. 8. -P. 553−559.
- Saarikoski S.T., Reinikainen M., Anttila S. et al. Role of NAT2 deficiency in susceptibility to lung cancer among asbestos-exposed individuals // Pharmacogenetics. -2000.-V. 10.-P. 183−185.
- Sadrieh N., Davis C.D., Snyderwine E.G. N-acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland // Cancer Res. 1996. — V. 56. — P.2683−2687.
- Sandy J., Mushtaq A., Holton S.J. et al. Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines // Biochem J. 2005. — V. 390. — P. 115−123.
- Sandy J., Mustaq A., Kawamura A. et al. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis an enzyme which inactivates the anti-tubercular drug, isoniazid // J. Mol. Biol. — 2002. — V. 318. — P. 1071−1083.
- Sasaki Y., Ohsako S., Deguchi T. Molecular and genetic analysis of arylamine N-acetyltransferase of rabbit liver // J. Biol. Chem. 1991. — V. 266. — P. 13 243−13 250.
- Sekine A., Saito S., Iida A. et al. Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT., NAT2, AANAT, ARD1, and LI CAM in the Japanese population // J. Hum. Genet. 2001. — V. 46. — P. 314 319.
- Seow A., Zhao B., Poh W-T. et al. NAT2 slow acetylator genotype is associated with increased risk of lung cancer among non-smoking Chinese women in Singapore // Carcinogenesis. 1999. — V. 20. — P. 1877−1881.
- Shastry B.S. SNP alleles in human disease and evolution // J. Hum. Genet. 2002. — V. 47.-P. 561−566.
- Shishikura K., Hohjoh H., Tokunaga K. Novel allele containing a 190C>T nonsynonymous substitution in the N-acetyltransferase (NAT2) gene // Hum. Mutat. -2000.-V. 15.-P. 581.
- Silverman E.K., Palmer L.J. Case-control association studies for the genetics of complex respiratory diseases // Am. J. Respir. Cell Mol. Biol. 2000. -V. 22. — P. 645 648.
- Sinclair J.C., Sandy J., Delgoda R., Sim E., Noble M.E. Structure of arylamine N-acetyltransferase reveals a catalytic triad // Nat. Struct. Biol. 2000. — V. 7. — P. 560−564.
- Sim E., Payton M., Noble M., Minchin R. An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eukaryotes and prokaryotes // Hum. Mol. Genet. 2000. — V. 9. — P. 2435−2441.
- Sim E., Pinter K., Mushtaq A. et al. Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function // Biochem. Soc. Trans. 2003. — V. 31. — P. 615−619.
- Sinclair J.C., Sandy J., Delgoda R., Sim E., Noble M.E. Structure of arylamine N-acetyltransferase reveals a catalytic triad // Nat. Struct. Biol. 2000. — V. 7. — P. 560−564.
- Sinclair J.C., Sim E. A fragment consisting of the first 204 amino-terminal amino acids of human arylamine N-acetyltransferase one (NAT1) and the first transacetylation step of catalysis // Biochem. Pharmacol. 1997. — V. 53. — P. 11−16.
- Slattery M.L., Edwards S., Curtin K. et al. Association between smoking, passive smoking, GSTM-1, NAT2, and rectal cancer // Cancer Epidemiol. Biomarkers Prev. -2003.-V. 12.-P. 882−889.
- Smelt V.A., Upton A., Adjaye J. et al. Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos // Hum. Mol. Genet. -2000. V. 9. — P. 1101−1107.
- Smith C.J., Livingston S.D., Doolittle D.J. An international literature survey of 'IARC Group I carcinogens' reported in mainstream cigarette smoke // Food Chem. Toxicol. 1997. — V. 35. — P. 1107−1130.
- Sorensen M., Autrup H., Tjonneland A. et al. Genetic polymorphisms in CYP1B1, GSTA1, NQOl and NAT2 and the risk of lung cancer // Cancer Lett. 2005. -V. 221.-P. 185−190.
- Soucek P., Skjelbred C.F., Svendsen M. et al. Single-track sequencing for genotyping of multiple SNPs in the N-acetyltransferase 1 (NAT1) // BMC Biotechnol. -2004.-V. 4.-P. 28.
- Sram R.J., Binkova B. Molecular epidemiology studies on occupational and environmental exposure to mutagens and carcinogens, 1997−1999. // Environ. Health Perspect. 2000. — V. 108. — P. 57−70.
- Svensson C.K., Drobitch R.K., Tomilo M. Effects of chloroquine and primaquine on rat liver cytosolic N-acetyltransferase activity // Biochem. Pharmacol. 1991. — V. 42. -P. 954−956.
- Svensson C.K., Tomilo M. Effect of H2-receptor antagonists on rat liver cytosolic acetylCoA: arylamine N-acetyltransferase activity // Drug Metab. Dispos. 1992. — V. 20.-P. 74−78.
- Tamer L., Ercan В., Ates N.A. N-acetyltransferase 2 gene polymorphism in patients with colorectal carcinoma // Cell Biochem. Funct. 2006. — V. 24. — P. 131−135.
- Tan E.K., Khajavi M., Thornby J.I. et al. Variability and validity of polymorphism association studies in Parkinson’s disease // Neurology. 2000. — V. 55. -P. 533−538.
- Tisdale J.E., Rudis M.I., Padhi I.D. et al. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans // J. Clin. Pharmacol. 1995. — V. 35. — P. 902−910.
- Toussaint C., Albin N., Massaad L. et al. Main drug- and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues // Cancer Res. 1993. — V. 53. — P. 4608−4612.
- Unal M., Tamer L., Akbas Y. et al. Genetic polymorphism of N-acetyltransferase 2 in the susceptibility to laryngeal squamous cell carcinoma // Head Neck. 2005. — V. 27.-P. 1056−1060.
- Upton A., Johnson N., Sandy J., Sim E. Arylamine N-acetyltransferases of mice, men and microorganisms // Trends Pharmacol. Sci. — 2001. — V. 22. — P. 140−146.
- Vatsis K.P., Weber W.W., Bell D.A. et al. Nomenclature for N-acetyltransferases //Pharmacogenetics. 1995. — V. 5. — P. 1−17.
- Walter R., Siegmund W., Scheuch E. Effect of interferon-gamma and streptolysin О on hepatic procainamide N-acetyltransferase and various microsomal cytochrome
- P450-dependent monooxygenases in rats // Immunopharmacol. Immunotoxicol. 1996. -V. 18.-P. 571−586.
- Wang C.Y., Debiec-Rychter M., Schut H.A.J, et al. N-acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium // Carcinogenesis. 1999. — V. 20. — P. 1591−1595.
- Wang H., Guo Z., Vath G.M. et al. Chemical modification of hamster arylamine N-acetyltransferase 2 with isozyme-selective and nonselective N-arylbromoacetamido reagents // Protein J. 2004. — V. 23. — P. 153−166.
- Weber W.W. Populations and genetic polymorphisms // Mol. Diagn. 1999. — V. 4.-P. 299−307.
- Weber W.W., Cohen S.N. N-acetylation and properties of an N-acetyltransferase from rabbit liver // Mol. Pharmacol. 1967. — V. 3. — P. 266−273.
- Weber W.W., Hein D.W. N-acetylation pharmacogenetics // Pharmacol. Rev. -1985.-V. 37.-P.25−79.
- Weber W.W., Vatsis K.P. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NATI) of peripheral blood // Pharmacogenetics. 1993. — V. 3. — P. 209−212.
- Welfare M.R., Cooper J., Bassendine M.F., Daly A.K. Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England // Carcinogenesis. 1997. — V. 18. — P. 1351−1354.
- Westwood I.M., Holton S.J., Rodrigues-Lima F. et al. Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase // Biochem. J. 2005. — V. 385. — P. 605−612.
- Wikman H., Thiel S., Jager B. et al. Relevance of N-acetyltransferase 1 and 2 {NATI, NATI) genetic polymorphisms in non-small cell lung cancer susceptibility // Pharmacogenetics. 2001. — V. 11. — P. 157−168.
- Willey J.C., Coy E. L, Brolly C. et al. Xenobiotic metabolism enzyme gene expression in human bronchial epithelial and alveolar macrophage cells // Am. J. Respir. Cell Mol. Biol. 1996. — V. 14. — P. 262−271.
- Williams J.A. Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression // Carcinogenesis. 2001. — V. 22. — P. 209−214.
- Windmill K.F., Gaedigk A., Hall P. de la M. et al. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues // Toxicol. Sci. 2000. — V. 54. — P. 19−29.
- Wohlleb J.C., Hunter C.F., Blass B. et al. Aromatic amine acetyltransferase as a marker for colorectal cancer: environmental and demographic associations // Int. J. Cancer. 1990. — V. 46. — P. 22−30.
- Wolkenstein P., Loriot M.A., Aractingi S. et al. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS // Pharmacogenetics. 2000. — V. 10. — P. 821 -828.
- Woolhouse N.W., Qureshi M.M., Bastaki S.M.A. et al. Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis // Pharmacogenetics. 1997. — V. 7. — P. 73−82.
- Woolhouse N.W., Qureshi M.M., Bayoumi R.A.L. A new mutation C759T in the polymorphic N-acetyltransferase (NAT2) gene // Pharmacogenetics. 1997. — V. 7. — P. 83−84.
- Zaher H., Svensson C.K. Glucocorticoid induction of hepatic acetyl CoA: arylamine N-acetyltransferase activity in the rat // Res. Commun. Chem. Pathol. Pharmacol. 1994. — V. 83. — P. 195−208.
- Zang Y., Zhao S., Doll M.A. et al. The T341C (Ilell4Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation // Pharmacogenetics. 2004. — V. 14. — P. 717−723.
- Zenser T.V., Lakshmi V.M., Rustan T.D. et al. Human N-acetylation of benzidin: role of NAT1 and NAT2 // Cancer Res. 1996. — V. 56. — P. 3941−3947.
- Zheng W., Deitz A. C, Campbell D.R. et al. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk // Cancer Epidemiol. Biomark. Prev. 1999. — V. 8. — P. 233−239.
- Zhu Y., Doll M.A., Hein D.W. Functional genomics of C190T single nucleotide polymorphism in human N-acetyltransferase 2 // Biol. Chem. 2002. — V. 383. — P. 983 987.
- Zhou Q., Talaska G., Jaeger M. et al. Benzidine-DNA adduct levels in human peripheral white blood cells significantly correlate with levels in exfoliated urothelial cells // Mutat. Res. 1997. — V. 393. — P. 199−205.
- Zhou W., Liu G., Thurston S.W. et al. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer // Cancer Epidemiol. Biomarkers Prev. 2002. — V. 11. — P. 15−21.
- Zielinska E., Nieewiarowski W., Bodarski G. et al. Arylamine N-acetyltransferase (NAT2) gene mutation in children with allergic deseases // Clin. Pharmacol. Ther. -1997.-V. 62.-P. 635−642.